CATALYST PHARMACEUTICALS INC (CPRX)
US14888U1016 - Common Stock
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s growth characteristics.
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals.
Why NASDAQ:CPRX qualifies as a high growth stock.
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing?
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease...
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET...
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (